Healthy Innovation Statement on COVID-19

Our thoughts are with those affected by the outbreak of COVID-19, the novel strain of the coronavirus, both here in Southeast Asia and around the globe. Addressing the global public health challenges presented by COVID-19 will require collaboration and partnership from stakeholders across the globe. Working together, governments, global health authorities and the private sector can develop solutions to diagnose, treat and prevent the further spread of COVID-19. Now, as always, policies that advance the benefits of healthy innovation are vital to solving public health crises.

For more information about how the industry is responding to the coronavirus crisis, please visit the International Federation of Pharmaceutical Manufacturers and Associations and the Pharmaceutical Research and Manufacturers of America.